VBL Therapeutics (VBLT) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Roth Reaffirms VBL Therapeutics (VBLT) at 'Buy'; Financing Overhang Removed, Partnership Now Key Focus
November 13, 2015 2:04 PM ESTRoth Capital reaffirms VBL Therapeutics (NASDAQ: VBLT) with a Buy rating and $22 price target after the company reported Q3 results... More
